Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow: 2017-2024

Historic Free Cash Flow for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to $25.4 million.

  • Kiniksa Pharmaceuticals International's Free Cash Flow rose 1564.36% to $33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.8 million, marking a year-over-year increase of 827.00%. This contributed to the annual value of $25.4 million for FY2024, which is 92.94% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Free Cash Flow stood at $25.4 million for FY2024, which was up 92.94% from $13.2 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Free Cash Flow's 5-year high stood at $25.4 million during FY2024, with a 5-year trough of -$136.8 million in FY2020.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Free Cash Flow had a median value of $13.2 million in 2023 and averaged $14.8 million.
  • Data for Kiniksa Pharmaceuticals International's Free Cash Flow shows a peak YoY soared of 130.99% (in 2023) over the last 5 years.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Free Cash Flow (Yearly) stood at -$136.8 million in 2020, then grew by 7.38% to -$126.7 million in 2021, then skyrocketed by 104.50% to $5.7 million in 2022, then soared by 130.99% to $13.2 million in 2023, then soared by 92.94% to $25.4 million in 2024.